NCCN Guidelines

Guidelines

• NCCN Guidelines Version 6.2024

Evidence Blocks

• NCCN Guidelines with Evidence Blocks Version 6.2024

Frameworks

• Basic Resources (English) Version 1.2024

• Core Resources (English) Version 1.2024

• Enhanced Resources (English) Version 1.2024

Guidelines for Patients

• Inflammatory Breast Cancer-English Version 2023

• Ductal Carcinoma In Situ-English Version 2024

• Invasive Breast Cancer-English Version 2024

• Metastatic Breast Cancer-English Version 2024

• Ductal Carcinoma In Situ-Spanish Version 2023

• Inflammatory Breast Cancer-Spanish Version 2023

• Invasive Breast Cancer-Spanish Version 2023

• Metastatic Breast Cancer-Spanish Version 2023

Educational Events and Programs

Calendar of Events

Continuing Education

• Archived Monthly Oncology Tumor Boards: Sequencing Therapies for Patients with Metastatic HER2-Negative Breast Cancer

• Multigene and Biomarker Testing in Breast Cancer

• Neoadjuvant/Adjuvant Treatment for Breast Cancer with SABCS Updates

• Locoregional Management of Breast Cancer with SABCS Updates

• Advances in the Management of Metastatic Breast Cancer with SABCS Updates

• Issues with Sexuality and Sexual Function in Patients with Breast Cancer

• Cardiovascular Health After Breast Cancer Treatment

• Team-Based Case Review: Breast Cancer

• Variations in Breast Cancer Screening Recommendations

• Updates to the Management of HR-Positive, HER2-Negative Breast Cancer

• NCCN Pharmacy Updates: Novel Therapies for Treating ESR1 and RET-Fusion Mutations in Breast Cancer

• NCCN Tumor Boards: Treatment Selection Strategies and Barriers to Clinical Care in Metastatic Breast Cancer

• Recorded Presentation from the NCCN Pharmacy Updates: Novel Therapies for Treating ESR1 and RET-Fusion Mutations in Breast Cancer

International

Disclosures

• Disclosure Policy

• Panel Member Disclosures

• Panel Member Disclosures by Meeting Date

• End User License Agreement